As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor, distinct from any previously ...